Sakamoto T, Ogino M, Yamamoto T, Mori H, Okinaga S, Arai K
Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo.
Nihon Sanka Fujinka Gakkai Zasshi. 1990 May;42(5):415-21.
Fundamental evaluation of the subrenal capsule assay (SRCA) method in nonsolid tumors was made, using two types of murine malignant ascites. Malignant ascites were obtained from mice bearing M-5076 ovarian reticular cell sarcoma or MH-134 hepatoma. These tumor cells were allowed to settle by standing at 4 degrees C to form a jelly-like clot. This clot was cut into fragments about 1mm3 in size and one of these fragments was mashed in trypan blue to estimate the viability grade of the implanted tumor cells. The rest of the fragments were implanted beneath the renal capsule of the mice. On the 6th day after implantation, the assay mice were killed, the increase in the size of the tumor was determined and histological examination was carried out. The results were as follows: (1) The clot was formed reproductively by allowing ascites to settle for one or two days and there was a high viability rate for the tumor cells: 79.9 +/- 11.0% of M-5076 and 90.1 +/- 5.9% of MH-134. (2) The ascites clot thus implanted grew rapidly in the control groups but growth was inhibited by chemotherapy: Tumors were reduced significantly (p less than 0.05-0.005) in the group treated with a single agent. This trend towards a suppressive effect of carcinocidal agents on the tumor growth was more conspicuous as a combination regimen was utilized, a combination of three agents producing the maximum effect. (3) The clot grew more quickly than the solid tumor in both the control and the treated groups. There was a high correlation (r = 0.93 in M-5076, and r = 0.64 in MH-134) between the growth rates of ascites and solid tumor in SRCA. (4) Histological examination revealed that viable tumor cells infiltrated widely under the renal capsule in both types of tumors. These results suggest that ascites and solid tumor are useful materials for the subrenal capsule assay method.
利用两种小鼠恶性腹水对肾包膜下接种法（SRCA）在非实体瘤中的基本评估进行了研究。恶性腹水取自患有M-5076卵巢网状细胞肉瘤或MH-134肝癌的小鼠。将这些肿瘤细胞在4℃静置使其沉降形成果冻状凝块。将该凝块切成约1mm3大小的碎片，其中一个碎片用台盼蓝捣碎以评估植入肿瘤细胞的活力等级。其余碎片植入小鼠肾包膜下。植入后第6天，处死检测小鼠，测定肿瘤大小的增加情况并进行组织学检查。结果如下：（1）通过让腹水沉降1或2天可重复性地形成凝块，且肿瘤细胞的活力率很高：M-5076的活力率为79.9±11.0%，MH-134的活力率为90.1±5.9%。（2）如此植入的腹水凝块在对照组中生长迅速，但化疗可抑制其生长：单药治疗组肿瘤显著缩小（p＜0.05 - 0.005）。随着联合用药方案的使用，杀癌剂对肿瘤生长的抑制作用趋势更明显，三种药物联合产生最大效果。（3）在对照组和治疗组中，凝块的生长均比实体瘤快。在SRCA中，腹水和实体瘤的生长速率之间存在高度相关性（M-5076中r = 0.93，MH-134中r = 0.64）。（4）组织学检查显示，在两种肿瘤中，存活的肿瘤细胞均在肾包膜下广泛浸润。这些结果表明，腹水和实体瘤是肾包膜下接种法的有用材料。
